PROM1 and glioblastoma: This latter observation is in accordance with that of Perazzoli et al. who concluded from their results that CD133 was unrelated to temozolomide resistance [47], but disagrees with others that have shown that CD133+ GBM cells are resistant to temozolomide [48].